<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152709</url>
  </required_header>
  <id_info>
    <org_study_id>JSEPI-003</org_study_id>
    <nct_id>NCT02152709</nct_id>
  </id_info>
  <brief_title>Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine</brief_title>
  <official_title>A Phase 3, Randomized, Controlled, and Blinded Clinical Trial to Evaluate Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine for Infants and Other Age Groups.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Biological Products Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Province Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study was to evaluate the safety and immunogenicity of 10µg/0.5ml&#xD;
      and 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in&#xD;
      saccharomyces cereviside yeast for infants and other age groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Within 28 days after hepatitis B vaccination</time_frame>
    <description>To analyze the number of subjects with adverse events within 28 days after administered each of hepatitis B vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean concentration of anti-hepatitis B virus surface antigen antibody</measure>
    <time_frame>The 28th day after whole course of hepatitis B vaccination</time_frame>
    <description>Geometric mean concentration of anti-hepatitis B virus surface antigen antibody was measured by chemiluminescence assay and expressed with mIU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of hepatitis B virus perinatal transmission</measure>
    <time_frame>The 28th day after whole course of hepatitis B vaccination</time_frame>
    <description>To analyze the rate of hepatitis B virus perinatal transmission after whole course of hepatitis B vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean concentration of anti-hepatitis B virus surface antigen antibody after the second dose of hepatitis B vaccination</measure>
    <time_frame>The 28th day after the second of hepatitis B vaccination</time_frame>
    <description>Geometric mean concentration of anti-hepatitis B virus surface antigen antibody was measured by chemiluminescence assay and expressed with mIU/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1537</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>10µg/0.5ml hepatitis B vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5µg/0.5ml hepatitis B vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3 dose of 10µg/0.5ml hepatitis B vaccine</intervention_name>
    <description>3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.</description>
    <arm_group_label>10µg/0.5ml hepatitis B vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3 dose of 5µg/0.5ml hepatitis B vaccine</intervention_name>
    <description>3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.</description>
    <arm_group_label>5µg/0.5ml hepatitis B vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (For Infant Group):&#xD;
&#xD;
          -  Healthy full-term infant after birth, Apgar score ≥7.&#xD;
&#xD;
          -  Guardian signed informed consent.&#xD;
&#xD;
          -  Guardian can comply with the requirements of the clinical trial.&#xD;
&#xD;
          -  Without administering immunoglobulin during the following period.&#xD;
&#xD;
          -  Axillary temperature ≤37.0 ℃.&#xD;
&#xD;
        Inclusion Criteria (For Other Age Groups):&#xD;
&#xD;
          -  More than 1 month old healthy people, without the history of hepatitis B infection.&#xD;
&#xD;
          -  Subjects or their guardians signed informed consent.&#xD;
&#xD;
          -  After questioning medical history, physical examination and being judged as healthy&#xD;
             subject.&#xD;
&#xD;
          -  Without the history of hepatitis B vaccination.&#xD;
&#xD;
          -  Subjects or their guardians can comply with requirements of the clinical trail.&#xD;
&#xD;
          -  Without other prevention drugs or immunoglobulin administered within two weeks before&#xD;
             the clinical trail or during the following period.&#xD;
&#xD;
          -  Axillary temperature ≤37.0 ℃.&#xD;
&#xD;
        Exclusion Criteria (For Infant Group):&#xD;
&#xD;
          -  Apgar score of infant after birth &lt;7.&#xD;
&#xD;
          -  With nervous system damage after birth, or with the family history of mental illness,&#xD;
             epilepsy or encephalopathy.&#xD;
&#xD;
          -  With immune system dysfunction.&#xD;
&#xD;
          -  With vitamin deficiency.&#xD;
&#xD;
          -  With acute febrile diseases, or infectious diseases.&#xD;
&#xD;
          -  With congenital malformations, developmental disorders or serious chronic illness.&#xD;
&#xD;
          -  With thrombocytopenia or other coagulation disorders.&#xD;
&#xD;
          -  Administered immunoglobulin during the period of the clinical trail, especially&#xD;
             administered Hepatitis B immunoglobulin to the infant of Hepatitis B infected mother.&#xD;
&#xD;
          -  With endemic disease.&#xD;
&#xD;
          -  Participate another clinical trial during the period of the clinical trail.&#xD;
&#xD;
          -  Any circumstance that may affect clinical trail evaluation.&#xD;
&#xD;
        Exclusion Criteria (For Other Age Groups):&#xD;
&#xD;
          -  With allergies, seizures, epilepsy, encephalopathy or with family history of mental&#xD;
             illness.&#xD;
&#xD;
          -  Allergic to any component of the study vaccine.&#xD;
&#xD;
          -  With immune system dysfunction.&#xD;
&#xD;
          -  Hepatitis B infected people.&#xD;
&#xD;
          -  Anti-HBs was positive screened by ELISA kit.&#xD;
&#xD;
          -  Either anti-HBs ≥10mIU/ml or HBsAg was positive screened by Radioimmunoassay method.&#xD;
&#xD;
          -  With acute febrile diseases or infectious diseases.&#xD;
&#xD;
          -  With congenital malformations, developmental disorders or serious chronic illness.&#xD;
&#xD;
          -  With thrombocytopenia or other coagulation disorders.&#xD;
&#xD;
          -  With the history of severe allergic reactions.&#xD;
&#xD;
          -  Administered other prevention drugs or immunoglobulin within two weeks before the&#xD;
             clinical trail or during the following period.&#xD;
&#xD;
          -  With any acute illness that requires antibiotics or anti-viral treatment within 7 days&#xD;
             before the clinical trail.&#xD;
&#xD;
          -  With vitamin deficiency.&#xD;
&#xD;
          -  With the history of febrile convulsion.&#xD;
&#xD;
          -  Axillary temperature ≥38.0 ℃ within 3 days before the clinical trail.&#xD;
&#xD;
          -  Participate another clinical trial during the period of the clinical trail.&#xD;
&#xD;
          -  Pregnant woman.&#xD;
&#xD;
          -  Any circumstance that may affect clinical trail evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fubao Ma, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

